Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-08-10
2003-10-21
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C546S113000, C546S114000, C546S115000, C546S116000, C546S119000, C544S127000, C544S262000, C544S350000, C514S300000, C514S301000, C514S302000, C514S303000, C540S597000
Reexamination Certificate
active
06635633
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a series of substituted pyrazoles, pharmaceutical compositions containing these compounds, and intermediates used in their manufacture, and methods of using them.
BACKGROUND OF THE INVENTION
Cathepsin S (EC 3.4.22.27) is a cysteine protease of the papain family found primarily in lysosomes (Bromme, D.; McGrath, M. E. High Level Expression and Crystallization of Recombinant Human Cathepsin S.
Protein Science
1996, 5, 789-791).
The role of cathepsin S in the immune response is anticipated by its tissue distribution: cathepsin S is found primarily in lymphatic tissues, lymph nodes, the spleen, B lymphocytes, and macrophages (Kirschke, H. Chapter 211. Cathepsin S. In Handbook of Proteolytic Enzymes. Barrett, A. J.; Rawlings, N. D.; Woessner, J. F., Eds. San Diego: Academic Press, 1998. pp. 621-624.). Cathepsin S inhibitors have been shown in animal models to modulate antigen presentation and are effective in an animal model of asthma (Riese, R. J.; Mitchell, R. N.; Villadangos, J. A.; Shi, G.-P.; Palmer, J. T.; Karp, E. R.; De Sanctis, G. T.; Ploegh, H. L.; Chapman, H. A. Cathepsin S Activity Regulates Antigen Presentation and Immunity.
J. Clin. Invest.
1998, 101, 2351-2363 and Shi, G.-P.; Villadangos, J. A.; Dranoff, G.; Small, C.; Gu, L.; Haley, K. J.; Riese, R.; Ploegh, H. L.; Chapman, H. A. Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development.
Immunity
1999, 10, 197-206.).
Mice in which the gene encoding cathepsin S has been knocked out are less susceptible to collagen-induced arthritis and their immune systems have an impaired ability to respond to antigens (Nakagawa, T. Y.; Brissette, W. H.; Lira, P. D.; Griffiths, R. J.; Petrushova, N.; Stock, J.; McNeish, J. D.; Eastman, S. E.; Howard, E. D.; Clarke, S. R. M.; Rosloniec, E. F.; Elliott, E. A.; Rudensky, A. Y. Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice.
Immunity
1999, 10, 207-217).
These data demonstrate that compounds that inhibit the proteolytic activity of human cathepsin S should find utility in the treatment of chronic autoimmune diseases including, but not limited to, lupus, rheumatoid arthritis, and asthma; and have potential utility in modulating the immune response to tissue transplantation.
There are a number of cathepsin S inhibitors reported in the literature. The most important patents are listed below.
Certain dipeptidyl nitrites are claimed by Novartis as cathepsin S inhibitors in: Altmann, et. al. WO-99/24460.
Dipeptidyl vinyl sulfones are claimed by Arris (now Axys) as cysteine protease (including cathepsin S) inhibitors in: Palmer, et. al. U.S. Pat. No. 5,976,858.
Certain peptidyl sulfonamides are claimed by Arris/Axys as cysteine protease (including cathepsin S) inhibitors in: Palmer, et. al. U.S. Pat. No. 5,776,718 (assigned to Arris, now Axys) & Klaus, et. al. U.S. Pat. No. 6,030,946 (assigned to Axys).
Compounds somewhat similar to those of the present invention are described in the following references.
Winters, et. al. (Winters, G.; Sala, A.; Barone, D.; Baldoli, E.
J. Med. Chem.
1985, 28, 934-940; Singh, P.; Sharma, R. C.
Quant. Struct.—Act. Relat.
1990, 9, 29-32; Winters, G.; Sala, A.; Barone, D. in U.S. Pat. No. 4,500,525 (1985)) have described bicyclic pyrazoles of the type shown below. R never contains a heterocyclic ring and no protease inhibitor activity is ascribed to these molecules; they are described as &agr;1-adrenergic receptor modulators.
Shutske, et. al. claim the bicylic pyrazoles below. The pyridine ring is aromatic in their system (Shutske, G. M.; Kapples, K. J.; Tomer, J. D. U.S. Pat. No. 5,264,576 (1993)). Although reference is made to R being a linker to a heterocycle, the claims specify only R=hydrogen. The compounds are referred to as serotonin reuptake inhibitors.
The compound 2-[4-[4-(3-methyl-5-phenyl-1H-pyrazol-1-yl)butyl]-1-piperazinyl]-pyrimidine is known from EP-382637, which describes pyrimidines having anxiolytic properties. This compound and analogs are further described in EP-502786 as cardiovascular and central nervous system agents. Pharmaceutical formulations with such compounds are disclosed in EP-655248 for use in the treatment of gastric secreation and as anti-ulcer agents. WO-9721439 describes medicaments with such compounds for treating obsessive-compulsive disorders, sleep apnea, sexual dysfunctions, emesis and motion sickness.
The compounds 5-methyl-3-phenyl-1-[4-(4-phenyl-1-piperazinyl)butyl]-1H-indazole and 5-bromo-3-(2-chlorophenyl)-1-[4-(4-phenyl-1-piperazinyl)butyl]-1H-indazole, in particular the hydrochloride salts thereof, are known from WO-9853940 and CA 122:314528, where these and similar compounds are described as kinase inhibitors in the former reference and possessing affinity for benzodiazepine receptors in the latter reference.
SUMMARY OF THE INVENTION
The present invention concerns compounds which can be represented by formula (I):
wherein:
the dashed line adjacent C—R
6
is absent or an sp
2
bond;
Y is nitrogen or R
20
C;
Z is nitrogen or R
21
C;
T is nitrogen or R
2
C;
S is nitrogen or R
3
C;
provided between 0 and 3 of S, T, Y, and Z are nitrogen; and further provided that one of S, T, Y, and Z can be ═N
+
—O
−
where the remaining three are not nitrogen;
R
20
is selected from hydrogen, halogen, C
1-5
alkoxy, hydroxy, C
1-5
alkyl, cyano, nitro, C
1-5
haloalkyl, R
o
R
p
N, R
o
R
p
NC═O, C
2-8
acyl, 4-7 membered heterocyclyl, (4-7 membered heterocyclyl)-C
1-5
alkylene, phenyl, (phenyl)C
1-5
alkylene, R
14
OC═O, R
14
S, R
14
SO, and R
14
SO
2
;
R
21
is selected from hydrogen, halogen, C
1-5
alkoxy, hydroxy, C
1-5
alkyl, cyano, nitro, C
1-5
haloalkyl, R
c
R
d
N, R
c
R
d
NC═O, C
2-8
acyl, 4-7 membered heterocyclyl, (4-7 membered heterocyclyl)-C
1-5
alkylene, phenyl, (phenyl)C
1-5
alkylene, R
15
OC═O, R
15
S, R
15
SO and R
15
SO
2
;
R
2
is selected from hydrogen, halogen, C
1-5
alkoxy, hydroxy, C
1-5
alkyl, cyano, nitro, C
5
haloalkyl, R
e
R
f
N, R
e
R
f
NC═O, C
2-8
acyl, 4-7 membered heterocyclyl, (4-7 membered heterocyclyl)-C
1-5
alkylene, phenyl, (phenyl)C
1-5
alkylene, R
16
OC═O, R
16
S, R
16
SO and R
16
SO
2
;
R
3
is selected from hydrogen, halogen, C
1-5
alkoxy, hydroxy, C
1-5
alkyl, cyano, nitro, C
1-5
haloalkyl, R
g
R
h
N, C
2-8
acyl, 4-7 membered heterocyclyl, (4-7 membered heterocyclyl)-C
1-5
alkylene, phenyl, (phenyl)C
1-5
alkylene, R
17
OC═O, R
m
R
n
NC═O, R
m
R
n
NSO
2
, R
17
S, R
17
SO and R
17
SO
2
;
R
5
and R
6
are independently selected from hydrogen and C
1-5
alkyl;
R
7
and R
8
independently are hydrogen, C
1-5
alkyl, C
1-5
alkenyl, C
1-5
alkoxy, C
1-5
alkylthio, halogen, or 4-7 membered carbocyclyl or heterocyclyl; alternatively, R
7
and R
8
can be taken together to form an optionally substituted 5- to 7-membered carbocyclic or heterocyclic ring, which ring may be unsaturated or aromatic; said ring being optionally substituted with between 1 and 3 substituents independently selected from halo, hydroxy, cyano, nitro, amino, R
t
, R
t
O—, R
t
S—, R
t
O(C
1-5
alkylene)-, R
t
O(C═O)—, R
t
(C═O)—, R
t
(C═S)—, R
t
(C═O)O—, R
t
O(C═O)(C═O)—, R
t
SO
2
, NHR
u
(C═NH)—, NHR
u
SO
2
—, and NHR
u
(C═O)—;
R
t
is C
1-6
alkyl, phenyl, benzyl, phenethyl, or C
2-5
heterocyclyl, (C
1-5
heterocyclyl)C
1-6
alkylene, NH
2
, mono- or di(C
1-6
alkyl)N—, or R
49
OR
50
—, wherein R
49
is H, C
1-5
alkyl, C
2-5
alkenyl, phenyl, benzyl, phenethyl, C
1-5
heterocyclyl, or (C
1-5
heterocyclyl)C
1-6
alkylene and R
50
is C
1-5
alkylene, phenylene, or divalent C
1-5
heterocyclyl; and
R
u
can be H in addition to the values for R
t
;
R
c
is hydrogen, C
1-5
alkyl, phenyl, C
2-5
heterocyclyl, C
2-8
acyl, aroyl, R
10
OC═O—, R
i
R
j
NC═O, R
10
SO—, R
10
SO
2
—, and R
i
R
j
NSO
2
;
R
e
is hydrogen, C
1-5
alkyl, phenyl, C
2-5
heterocyclyl, C
2-8
acyl, aroyl, R
40
OC═O, R
43
R
44
NC═O, R
40
SO, R
40
Cai Hui
Edwards James P.
Meduna Steven P.
Pio Barbara A.
Wei Jianmei
Berch Mark L.
Hable Kahsay
Ortho-Pharmaceutical, Inc.
LandOfFree
Substituted pyrazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazoles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3142654